Legal status in the United States
Is TB-500 legal?
Read at FDA, DEA and WADAPublished by PepVault
TB-500 has no FDA-approved product, is not a federally controlled substance, and is banned in sport (WADA names it under S2.3), as of November 18, 2026.
TB-500 at a glance
| Check | Status, read Nov 18, 2026 |
|---|---|
| FDA approval | Not approved |
| Compounding | Nomination withdrawn; on no FDA list |
| DEA schedule | Not controlled |
| Sport (WADA) | Banned, named (S2.3) |
FDA approval
TB-500 has no FDA-approved product: Drugs@FDA lists no application for it or for thymosin beta-4.
- Drugs@FDA data (openFDA): applications listing “THYMOSIN” as an active ingredient, U.S. Food and Drug Administration. Read .

Compounding
FDA once placed TB-500 (thymosin beta-4 fragment LKKTETQ) in category 2, its list of bulk substances that may raise significant safety risks; the nominations were then withdrawn, and FDA now lists it under “Bulk drug substances nominated but withdrawn.” It is in none of the three 503A categories on FDA’s list updated May 14, 2026, and not on the 503B bulks list. FDA took TB-500 to its Pharmacy Compounding Advisory Committee on July 23, 2026, for wound healing, and proposed that it “NOT be included” on the 503A bulks list; the committee’s vote is not on FDA’s meeting page, and TB-500 is not on the 503A bulks list itself (21 CFR 216.23).
The source: “Bulk drug substances nominated but withdrawn”
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks (content current as of April 22, 2026), U.S. Food and Drug Administration. Read .
- Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act (updated May 14, 2026), U.S. Food and Drug Administration. Read .
- 503B Bulk Drug Substances List (content current as of May 16, 2024), U.S. Food and Drug Administration. Read .
- July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee (content current as of August 6, 2026), U.S. Food and Drug Administration. Read .
- FDA Briefing Document, Pharmacy Compounding Advisory Committee (PCAC) Meeting, July 23-24, 2026, U.S. Food and Drug Administration. Read .
- 21 CFR 216.23, Bulk drug substances that can be used to compound drug products in accordance with section 503A (eCFR, up to date as of November 16, 2026), Electronic Code of Federal Regulations. Read .
DEA schedule
It is not a federally controlled substance: its name is not in the DEA’s schedules (21 CFR Part 1308) or on the DEA’s alphabetical list of controlled substances.
- 21 CFR Part 1308, Schedules of Controlled Substances (eCFR, up to date as of November 16, 2026), Electronic Code of Federal Regulations. Read .
- Controlled Substances, Alphabetical Order (dated November 17, 2026), Drug Enforcement Administration, Diversion Control Division. Read .
Sport (WADA)
WADA bans TB-500 at all times, in and out of competition: the 2026 list names it under S2.3, as a derivative of thymosin beta-4.
The source: “Thymosin-β4 and its derivatives e.g. TB-500”
- World Anti-Doping Code International Standard, Prohibited List 2026 (in effect from January 1, 2026), World Anti-Doping Agency. Read .
How it is sold when it isn’t approved
FDA has warned companies that sold unapproved GLP-1 drugs labeled “for research purposes” or “not for human consumption” to consumers with dosing instructions, and calls that label false. FDA’s page names GLP-1 drugs; a research label is not an FDA approval of any kind.
The source: falsely labeled “for research purposes” or “not for human consumption.”
- FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss (content current as of October 1, 2026), U.S. Food and Drug Administration. Read .
What this means and doesn’t
This page reports what the agencies’ own pages said about TB-500 in the United States when we read them on November 18, 2026. These are records of regulators, not study evidence; for what the research shows, see the compound page.
It is not legal advice, and it doesn’t cover state laws or other countries, whose rules differ. Agencies change their lists, so each fact carries its date and a link to the page it came from.
Questions
Is TB-500 FDA approved?
TB-500 has no FDA-approved product: Drugs@FDA lists no application for it or for thymosin beta-4.
Is TB-500 a controlled substance?
It is not a federally controlled substance: its name is not in the DEA’s schedules (21 CFR Part 1308) or on the DEA’s alphabetical list of controlled substances.
Is TB-500 banned in sport?
WADA bans TB-500 at all times, in and out of competition: the 2026 list names it under S2.3, as a derivative of thymosin beta-4.
What does FDA say about compounding TB-500?
FDA once placed TB-500 (thymosin beta-4 fragment LKKTETQ) in category 2, its list of bulk substances that may raise significant safety risks; the nominations were then withdrawn, and FDA now lists it under “Bulk drug substances nominated but withdrawn.” It is in none of the three 503A categories on FDA’s list updated May 14, 2026, and not on the 503B bulks list. FDA took TB-500 to its Pharmacy Compounding Advisory Committee on July 23, 2026, for wound healing, and proposed that it “NOT be included” on the 503A bulks list; the committee’s vote is not on FDA’s meeting page, and TB-500 is not on the 503A bulks list itself (21 CFR 216.23).
What does FDA say about the “research use only” label?
FDA has warned companies that sold unapproved GLP-1 drugs labeled “for research purposes” or “not for human consumption” to consumers with dosing instructions, and calls that label false. FDA’s page names GLP-1 drugs; a research label is not an FDA approval of any kind.